Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Quest Diagnostics CEO and President J. E. Davis reported mixed equity transactions involving company stock. On a grant date of March 4, 2026, Davis acquired 51,652 shares of Quest Diagnostics common stock at a price of $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). In a related move, 26,414 shares of common stock were disposed of back to the issuer at $204.86 per share to cover tax withholding obligations from the settlement. After these transactions, Davis directly held 142,423 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president for Diagnostic Services Patrick Plewman reported a mix of stock award activity, tax-related share disposition, and an open-market sale of common stock. On March 4, he acquired 5,682 shares as a grant or award at $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). On the same date, 2,827 shares were disposed of at $204.86 per share to Quest Diagnostics to cover tax withholding obligations from that award, leaving 18,053 shares directly owned afterward. On March 5, he sold 2,855 shares of common stock in an open-market transaction at $206.21 per share under a pre-arranged Rule 10b5-1 trading plan, resulting in direct ownership of 15,198 shares.
Quest Diagnostics executive Michael J. Deppe reported offsetting equity transactions involving company stock. He acquired 1,473 shares of Quest Diagnostics common stock on a grant/award basis tied to a performance stock award, valued at $204.86 per share, increasing his holdings at that moment to 35,946 shares.
On the same date, 750 shares were disposed of back to Quest Diagnostics at $204.86 per share solely to cover tax withholding obligations arising from the settlement of that performance stock award. After the tax-withholding disposition, Deppe directly owned 35,196 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president Karthik Kuppusamy reported a mix of equity award activity and related share disposition. He acquired 6,200 shares of common stock on March 4, 2026 as stock issued in settlement of a performance stock award approved under Rule 16b-3(d). To cover tax withholding from this award, 2,628 shares of common stock at $204.86 per share were disposed of back to the issuer. After these transactions, he held 13,441 shares directly, plus additional indirect holdings of 358 shares by trust and 1,658 shares in a 401(k) plan, based on information from the plan administrator.
DGX files a Rule 144 notice to sell 3,878 common shares tied to restricted stock vesting on 02/23/2026.
The filing also reports recent sales by Michael Prevoznik of 1,111 shares on 02/19/2026 for $227,566.13 and 526 shares on 03/03/2026 for $109,265.98.
Catherine T. Doherty reported sales of Common Stock under a Form 144 notice. The excerpt lists three open-market transactions: 26,165 shares on 02/13/2026, 1,433 shares on 02/19/2026, and 632 shares on 03/03/2026. The broker listed is Fidelity Brokerage Services LLC.
Thomas P. Plewman reported sales of common stock via Form 144. The filing lists multiple dispositions: 5,662 shares (sale proceeds $1,155,048.00) on 02/10/2026, 958 shares (proceeds $196,227.14) on 02/19/2026, and 410 shares (proceeds $85,169.30) on 03/03/2026. The excerpt also shows 2,855 shares from a restricted stock vesting entry dated 02/23/2026.
Quest Diagnostics executive Catherine T. Doherty reported sales and related share dispositions of company stock. On March 3, 2026, she executed an open-market sale of 632 shares of common stock at $207.73 per share, leaving 67,122 shares held directly.
On March 2, 2026, 648 shares were disposed of at $204.86 per share to cover tax obligations tied to the vesting of restricted share units, and the sale activity was carried out under a pre-arranged Rule 10b5-1 trading plan. She also holds 4,502 shares indirectly through a company 401(k)/profit sharing plan.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported a Form 4 transaction involving common stock. On the reported date, he disposed of 869 shares at $204.86 per share in a tax-withholding transaction tied to the vesting of a prior restricted stock unit grant. This was a sale of shares to satisfy tax obligations rather than an open-market trade. After this transaction, he directly owned 27,041 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president and general counsel Michael E. Prevoznik reported recent stock transactions. On March 3, he executed an open-market sale of 526 shares of common stock at $207.73 per share under a Rule 10b5-1 sales plan, leaving 37,557 shares held directly afterward. On March 2, 288 shares were disposed of at $204.86 per share to cover tax obligations from the vesting of restricted share units. He also has 5,737 shares held indirectly through company 401(k) and deferred compensation plans.